{"id":448,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tirzepatide-approved-drug-vs-research-material","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/tirzepatide-approved-drug-vs-research-material\/","title":{"rendered":"Tirzepatide dans 2026\u00a0:\u00a0preuves approuv\u00e9es sur les m\u00e9dicaments par rapport au mat\u00e9riel destin\u00e9 \u00e0 la recherche"},"content":{"rendered":"
Le mot \u00ab tirz\u00e9patide \u00bb peut appara\u00eetre dans un m\u00e9dicament approuv\u00e9 par FDA, un article clinique, une discussion sur un produit compos\u00e9 ou un catalogue de laboratoire. Ces contextes ne sont pas interchangeables. Le statut r\u00e9glementaire s'attache \u00e0 un produit fini sp\u00e9cifique et \u00e0 son application approuv\u00e9e, et non \u00e0 un nom isol\u00e9.<\/p>
Points cl\u00e9s \u00e0 retenir<\/h2>
L'approbation FDA est sp\u00e9cifique au produit et comprend des obligations contr\u00f4l\u00e9es en mati\u00e8re de fabrication, de formulation, d'\u00e9tiquetage et de post-commercialisation.<\/li>
Une liste d\u2019utilisation \u00e0 des fins de recherche n\u2019est pas approuv\u00e9e parce qu\u2019elle partage le nom d\u2019un ingr\u00e9dient actif.<\/li>
L'examen des achats doit se concentrer sur l'utilisation pr\u00e9vue, le statut juridique, l'identit\u00e9 et les enregistrements de qualit\u00e9 sp\u00e9cifiques au lot.<\/li><\/ul><\/div><\/div>Illustration conceptuelle de recherche sur les r\u00e9cepteurs g\u00e9n\u00e9r\u00e9e pour cet article\u00a0; il ne repr\u00e9sente pas une pr\u00e9sentation de m\u00e9dicament approuv\u00e9e ou un lot de catalogue.<\/figcaption><\/figure>
Quatre enregistrements qui ne devraient pas \u00eatre regroup\u00e9s en un seul<\/h2>
Une \u00e9tiquette approuv\u00e9e d\u00e9crit un m\u00e9dicament fini particulier. Un article \u00e9valu\u00e9 par des pairs d\u00e9crit l'intervention et le protocole utilis\u00e9s dans cette \u00e9tude. Un dossier de composition concerne un parcours juridique et de fabrication distinct. Un catalogue de recherche d\u00e9crit le mat\u00e9riel propos\u00e9 pour les travaux de laboratoire. Chaque enregistrement r\u00e9pond \u00e0 des questions diff\u00e9rentes.<\/p>
M\u00e9dicament approuv\u00e9 par FDA<\/strong>Application sp\u00e9cifique, formulation, \u00e9tiquetage, contr\u00f4les de fabrication et utilisation approuv\u00e9e<\/span><\/div>
Mat\u00e9riel d'essai clinique<\/strong>Intervention contr\u00f4l\u00e9e selon un protocole d'\u00e9tude<\/span><\/div>
Pr\u00e9paration compos\u00e9e<\/strong>Cat\u00e9gorie r\u00e9glementaire distincte\u00a0; il ne s'agit pas d'un m\u00e9dicament fini approuv\u00e9 par FDA<\/span><\/div>
Mat\u00e9riel destin\u00e9 \u00e0 la recherche<\/strong>Mat\u00e9riel de laboratoire\u00a0; pas d'usage humain ou v\u00e9t\u00e9rinaire<\/span><\/div><\/div><\/div>
Ce qu'une page de catalogue pr\u00e9cise peut dire<\/h2>
Une page de catalogue peut indiquer les champs d'identit\u00e9 v\u00e9rifi\u00e9s, les tailles de conditionnement disponibles, les sp\u00e9cifications analytiques, la disponibilit\u00e9 des documents et le contexte de la recherche. Il peut \u00e9tablir un lien avec la litt\u00e9rature clinique tout en expliquant clairement que la litt\u00e9rature ne valide pas le lot fourni.<\/p>
Il ne doit pas emprunter une indication approuv\u00e9e, impliquer une \u00e9quivalence th\u00e9rapeutique, reproduire les instructions d'administration ou pr\u00e9senter les pourcentages de r\u00e9sultats cliniques comme les r\u00e9sultats attendus du produit catalogue.<\/p>
Une liste de contr\u00f4le de r\u00e9vision pratique<\/h2>
Confirmez d\u2019abord l\u2019utilisation pr\u00e9vue. Faites ensuite correspondre le nom du produit, la forme chimique, le num\u00e9ro de catalogue et le lot sur le devis, l'\u00e9tiquette et le certificat. Passez en revue les m\u00e9thodes analytiques nomm\u00e9es et demandez des donn\u00e9es \u00e0 l\u2019appui lorsque l\u2019exp\u00e9rience a des exigences strictes en mati\u00e8re de puret\u00e9, d\u2019agr\u00e9gation ou d\u2019identit\u00e9.<\/p>
Conservez la documentation sur les m\u00e9dicaments approuv\u00e9s dans un dossier de preuves distinct du dossier sur la qualit\u00e9 du mat\u00e9riel de recherche. Cette simple s\u00e9paration \u00e9vite de nombreuses all\u00e9gations trompeuses d\u2019\u00e9quivalence.<\/p>","protected":false},"excerpt":{"rendered":"
Pourquoi un m\u00e9dicament tirz\u00e9patide approuv\u00e9 par FDA, un produit compos\u00e9 et un catalogue d'utilisation pour la recherche ne sont pas des cat\u00e9gories de preuves interchangeables.<\/p>","protected":false},"author":1,"featured_media":618,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"370","pim_article_type":"Regulatory and quality boundary","pim_evidence_level":"FDA regulatory records and product-quality principles","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA prescribing information for Mounjaro (tirzepatide)\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf\",\"note\":\"Product-specific approved labeling.\"},{\"title\":\"FDA information on unapproved GLP-1 products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Regulatory distinctions and current safety concerns.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-448","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material - NHD<\/title>\n<meta name=\"description\" content=\"Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/tirzepatide-approved-drug-vs-research-material\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material\" \/>\n<meta property=\"og:description\" content=\"Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/tirzepatide-approved-drug-vs-research-material\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/\"},\"wordCount\":332,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/\",\"name\":\"Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-approved-drug-vs-research-material\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tirzepatide dans 2026\u00a0: Preuves approuv\u00e9es sur les m\u00e9dicaments par rapport aux mat\u00e9riaux destin\u00e9s \u00e0 la recherche - NHD","description":"Pourquoi un m\u00e9dicament tirz\u00e9patide approuv\u00e9 par FDA, un produit compos\u00e9 et un catalogue d'utilisation pour la recherche ne sont pas des cat\u00e9gories de preuves interchangeables.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/tirzepatide-approved-drug-vs-research-material\/","og_locale":"fr_FR","og_type":"article","og_title":"Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material","og_description":"Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.","og_url":"https:\/\/nhdbio.com\/fr\/tirzepatide-approved-drug-vs-research-material\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/"},"wordCount":332,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/","url":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/","name":"Tirzepatide dans 2026\u00a0: Preuves approuv\u00e9es sur les m\u00e9dicaments par rapport aux mat\u00e9riaux destin\u00e9s \u00e0 la recherche - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Pourquoi un m\u00e9dicament tirz\u00e9patide approuv\u00e9 par FDA, un produit compos\u00e9 et un catalogue d'utilisation pour la recherche ne sont pas des cat\u00e9gories de preuves interchangeables.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-approved-drug-vs-research-material-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tirzepatide-approved-drug-vs-research-material\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=448"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/448\/revisions"}],"predecessor-version":[{"id":523,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/448\/revisions\/523"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/618"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Chercheur](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")